This Company is way undervalued as we all know.Testing in all...

This Company is way undervalued as we all know.
Testing in all areas that GSS has a footprint are all at record levels. Uk & Boston are coming into winter and the numbers for Q2 & Q3 will be significant in these regions.

Another quarter of $10-$12m is on the cards - Q3 will be as good if not better IMO.

if this is the case does the Company need to discose to the market that Half year sales will almost exceed FY20 full year sales? There should be close to $40m+ in the kitty by FY22 - not a bad result ! We are cashed up and could look for a significant acquisition to bolster future revenues.

we still need a steady news flow from the Company, and this is where they are lagging behind;

Some positive news will assist our SP and not just on twitter:
- FDA approvals and/or TGA approvals
- New contracts with any major hospital or customer which is material.
- updates on forecast for FY 22

Patience will be rewarded here!